Antiphospholipid antibodies in patients with coronary artery disease

New cardiac risk factors?

Tom P. Greco, Ann Marie Conti-Kelly, Eiji Matsuura, Tom Greco, Ken J. Dier, Gregory Svanas, Robin Doyle, Luis R. Lopez

Research output: Chapter in Book/Report/Conference proceedingConference contribution

10 Citations (Scopus)

Abstract

Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute coronary syndromes (ACS) to determine if aPL were associated with the presence and severity of CAD, adverse outcomes, and other coronary risk factors. Patients with chest pain/ACS were evaluated for aPL prior to diagnostic and therapeutic investigations. Coronary angiograms were graded according to the severity of disease. Risk factors, including family histories, were assessed and patients were followed for adverse outcomes. To date, 232 patients (116 M, 116 F, mean age 63 years) with a mean follow-up of 9 months were studied. Thirty-seven percent (86/232) were positive for one or more aPL. More women, 49/86 (57%), were aPL positive versus men, 37/86 (43%). The presence of aPL appeared associated with both presence and severity of CAD(P = 0.176 women; P = 0.163 men). In patients undergoing procedures (angioplasty, stent, bypass), aPL was significantly associated with both an increase in adverse cardiac outcomes (P = 0.045) and extracardiac thrombotic events (P = 0.033). Anti-β2 glycoprotein-1 (aβ2GP1) was the most frequent aPL, occurring in 68.5% of aPL-positive patients with CAD. Anticardiolipin antibody (aCL) occurred in only 7.4%. IgM isotypes were the most frequent for all categories of aPL (range 55-90%). Family history of antiphospholipid syndrome (APS)-related events was more significant in aPL-positive than aPL-negative individuals (P = 0.027).

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages466-474
Number of pages9
Volume1108
DOIs
Publication statusPublished - Jun 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1108
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Antiphospholipid Antibodies
Coronary Artery Disease
Acute Coronary Syndrome
Chest Pain
Anticardiolipin Antibodies
Stents
Antiphospholipid Syndrome
Angioplasty
Immunoglobulin M
Glycoproteins
Angiography

Keywords

  • β2GP1 antibodies
  • Acute coronary syndromes
  • Antiphospholipid syndrome
  • Cardiac risk

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Greco, T. P., Conti-Kelly, A. M., Matsuura, E., Greco, T., Dier, K. J., Svanas, G., ... Lopez, L. R. (2007). Antiphospholipid antibodies in patients with coronary artery disease: New cardiac risk factors? In Annals of the New York Academy of Sciences (Vol. 1108, pp. 466-474). (Annals of the New York Academy of Sciences; Vol. 1108). https://doi.org/10.1196/annals.1422.049

Antiphospholipid antibodies in patients with coronary artery disease : New cardiac risk factors? / Greco, Tom P.; Conti-Kelly, Ann Marie; Matsuura, Eiji; Greco, Tom; Dier, Ken J.; Svanas, Gregory; Doyle, Robin; Lopez, Luis R.

Annals of the New York Academy of Sciences. Vol. 1108 2007. p. 466-474 (Annals of the New York Academy of Sciences; Vol. 1108).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Greco, TP, Conti-Kelly, AM, Matsuura, E, Greco, T, Dier, KJ, Svanas, G, Doyle, R & Lopez, LR 2007, Antiphospholipid antibodies in patients with coronary artery disease: New cardiac risk factors? in Annals of the New York Academy of Sciences. vol. 1108, Annals of the New York Academy of Sciences, vol. 1108, pp. 466-474. https://doi.org/10.1196/annals.1422.049
Greco TP, Conti-Kelly AM, Matsuura E, Greco T, Dier KJ, Svanas G et al. Antiphospholipid antibodies in patients with coronary artery disease: New cardiac risk factors? In Annals of the New York Academy of Sciences. Vol. 1108. 2007. p. 466-474. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1422.049
Greco, Tom P. ; Conti-Kelly, Ann Marie ; Matsuura, Eiji ; Greco, Tom ; Dier, Ken J. ; Svanas, Gregory ; Doyle, Robin ; Lopez, Luis R. / Antiphospholipid antibodies in patients with coronary artery disease : New cardiac risk factors?. Annals of the New York Academy of Sciences. Vol. 1108 2007. pp. 466-474 (Annals of the New York Academy of Sciences).
@inproceedings{9331dffe82f44b2fae0715eafe9d1de2,
title = "Antiphospholipid antibodies in patients with coronary artery disease: New cardiac risk factors?",
abstract = "Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute coronary syndromes (ACS) to determine if aPL were associated with the presence and severity of CAD, adverse outcomes, and other coronary risk factors. Patients with chest pain/ACS were evaluated for aPL prior to diagnostic and therapeutic investigations. Coronary angiograms were graded according to the severity of disease. Risk factors, including family histories, were assessed and patients were followed for adverse outcomes. To date, 232 patients (116 M, 116 F, mean age 63 years) with a mean follow-up of 9 months were studied. Thirty-seven percent (86/232) were positive for one or more aPL. More women, 49/86 (57{\%}), were aPL positive versus men, 37/86 (43{\%}). The presence of aPL appeared associated with both presence and severity of CAD(P = 0.176 women; P = 0.163 men). In patients undergoing procedures (angioplasty, stent, bypass), aPL was significantly associated with both an increase in adverse cardiac outcomes (P = 0.045) and extracardiac thrombotic events (P = 0.033). Anti-β2 glycoprotein-1 (aβ2GP1) was the most frequent aPL, occurring in 68.5{\%} of aPL-positive patients with CAD. Anticardiolipin antibody (aCL) occurred in only 7.4{\%}. IgM isotypes were the most frequent for all categories of aPL (range 55-90{\%}). Family history of antiphospholipid syndrome (APS)-related events was more significant in aPL-positive than aPL-negative individuals (P = 0.027).",
keywords = "β2GP1 antibodies, Acute coronary syndromes, Antiphospholipid syndrome, Cardiac risk",
author = "Greco, {Tom P.} and Conti-Kelly, {Ann Marie} and Eiji Matsuura and Tom Greco and Dier, {Ken J.} and Gregory Svanas and Robin Doyle and Lopez, {Luis R.}",
year = "2007",
month = "6",
doi = "10.1196/annals.1422.049",
language = "English",
isbn = "157331708X",
volume = "1108",
series = "Annals of the New York Academy of Sciences",
pages = "466--474",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Antiphospholipid antibodies in patients with coronary artery disease

T2 - New cardiac risk factors?

AU - Greco, Tom P.

AU - Conti-Kelly, Ann Marie

AU - Matsuura, Eiji

AU - Greco, Tom

AU - Dier, Ken J.

AU - Svanas, Gregory

AU - Doyle, Robin

AU - Lopez, Luis R.

PY - 2007/6

Y1 - 2007/6

N2 - Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute coronary syndromes (ACS) to determine if aPL were associated with the presence and severity of CAD, adverse outcomes, and other coronary risk factors. Patients with chest pain/ACS were evaluated for aPL prior to diagnostic and therapeutic investigations. Coronary angiograms were graded according to the severity of disease. Risk factors, including family histories, were assessed and patients were followed for adverse outcomes. To date, 232 patients (116 M, 116 F, mean age 63 years) with a mean follow-up of 9 months were studied. Thirty-seven percent (86/232) were positive for one or more aPL. More women, 49/86 (57%), were aPL positive versus men, 37/86 (43%). The presence of aPL appeared associated with both presence and severity of CAD(P = 0.176 women; P = 0.163 men). In patients undergoing procedures (angioplasty, stent, bypass), aPL was significantly associated with both an increase in adverse cardiac outcomes (P = 0.045) and extracardiac thrombotic events (P = 0.033). Anti-β2 glycoprotein-1 (aβ2GP1) was the most frequent aPL, occurring in 68.5% of aPL-positive patients with CAD. Anticardiolipin antibody (aCL) occurred in only 7.4%. IgM isotypes were the most frequent for all categories of aPL (range 55-90%). Family history of antiphospholipid syndrome (APS)-related events was more significant in aPL-positive than aPL-negative individuals (P = 0.027).

AB - Antiphospholipid antibodies (aPL) have been implicated in the pathogenesis of coronary artery disease (CAD). We evaluated the presence of aPL in patients with chest pain/acute coronary syndromes (ACS) to determine if aPL were associated with the presence and severity of CAD, adverse outcomes, and other coronary risk factors. Patients with chest pain/ACS were evaluated for aPL prior to diagnostic and therapeutic investigations. Coronary angiograms were graded according to the severity of disease. Risk factors, including family histories, were assessed and patients were followed for adverse outcomes. To date, 232 patients (116 M, 116 F, mean age 63 years) with a mean follow-up of 9 months were studied. Thirty-seven percent (86/232) were positive for one or more aPL. More women, 49/86 (57%), were aPL positive versus men, 37/86 (43%). The presence of aPL appeared associated with both presence and severity of CAD(P = 0.176 women; P = 0.163 men). In patients undergoing procedures (angioplasty, stent, bypass), aPL was significantly associated with both an increase in adverse cardiac outcomes (P = 0.045) and extracardiac thrombotic events (P = 0.033). Anti-β2 glycoprotein-1 (aβ2GP1) was the most frequent aPL, occurring in 68.5% of aPL-positive patients with CAD. Anticardiolipin antibody (aCL) occurred in only 7.4%. IgM isotypes were the most frequent for all categories of aPL (range 55-90%). Family history of antiphospholipid syndrome (APS)-related events was more significant in aPL-positive than aPL-negative individuals (P = 0.027).

KW - β2GP1 antibodies

KW - Acute coronary syndromes

KW - Antiphospholipid syndrome

KW - Cardiac risk

UR - http://www.scopus.com/inward/record.url?scp=34948825878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948825878&partnerID=8YFLogxK

U2 - 10.1196/annals.1422.049

DO - 10.1196/annals.1422.049

M3 - Conference contribution

SN - 157331708X

SN - 9781573317085

VL - 1108

T3 - Annals of the New York Academy of Sciences

SP - 466

EP - 474

BT - Annals of the New York Academy of Sciences

ER -